|
| |
PharmexaPharmexa is a leading biotech company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. The company has been listed on the Copenhagen Stock Exchange since 2000. The Pharmexa group consists of GemVax AS, a Norwegian subsidiary, developing peptide vaccines for cancer and Pharmexa-Epimmune, a US subsidiary, focusing on T cell epitope-based vaccines for cancer and infectious diseases.Pharmexa's lead programs include a proprietary peptide vaccine targeting telomerase in phase III, a recombinant protein vaccine targeting HER-2 currently in phase II and several vaccine candidates for HIV therapy and prophylaxis currently in phase I. Earlier programs target RANKL, TNF-alpha, malaria, influenza and other promising targets
| Contact Details: |
| Medicon Valley, in the Science Park |
| Hørsholm |
| |
| DK-2970 |
| Denmark |
| Tel: | 45 45 16 25 25 |
| Fax: | 45 45 16 25 00 |
| Email: | Info@Pharmexa.com |
| WWW: | www.me.dk/
|
| |
Recent Publications by Pharmexa: |  |
Design and preclinical development of a recombinant protein and DNA plasmid mixed format vaccine to deliver HIV-derived T-lymphocyte epitopes.
Coordinated interactions between helper and cytotoxic T-lymphocytes (HTL... | 30th September, 2009
| Pharmexa Inc., San Diego, CA, USA.
| Vaccine. 2009 Nov 23;27(50):7087-95. Epub 2009 Sep 26.
DOI Direct Link |
Formulation and Characterization of a Ten-peptide Single-vial Vaccine, EP-2101, Designed to Induce Cytotoxic T-lymphocyte Responses for Cancer Immunotherapy.
Effective vaccines that mediate clinical responses in cancer patients may... | 3rd April, 2008
| Pharmexa-Epimmune Inc., 5820 Nancy Ridge Drive, Suite 100, San Diego, CA
| Hum Vaccin. 2007 Nov 11;4(3).
|
Breaking B-cell tolerance and CTL tolerance in three OVA-transgenic mouse strains expressing different levels of OVA.
It is of major importance to overcome the immunological tolerance in... | 13th February, 2008
| Pharmexa A/S, Kogle Alle 6, Horsholm, Denmark.
| Scand J Immunol. 2008 Feb;67(2):113-20.
DOI Direct Link |
Perspectives on the development of a therapeutic HER-2 cancer vaccine.
With good reason, the majority of cancer vaccines tested, or being tested,... | 17th January, 2008
| Pharmexa A/S, Kogle
| Vaccine. 2007 Sep 27;25 Suppl 2:B17-23. Epub 2007 Jun 18.
DOI Direct Link |
Generation of autoreactive CTL by tumour vaccines containing foreign T helper epitopes.
The aim of this study was to evaluate the effect of including a foreign T... | 5th May, 2007
| Pharmexa A/S, Horsholm, Denmark.
| Scand J Immunol. 2007 Mar;65(3):240-8.
DOI Direct Link |
→View more Pharmexa research publications. |
Press Releases on Pharmexa:
|
 |
| Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment |
26th October, 2009 |
Reportlinker |
-- A focus on "engineered" antibodies
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing
|
| Affitech Strengthens Patent Position on its Phagemid Antibody Screening Technology in Europe |
2nd April, 2009 |
Affitech AS |
OSLO, Norway, April 2 /PRNewswire/ -- The human antibody company, Affitech AS announced today that the European Patent Office has granted an European patent on the use of phagemid particles having an
|
| Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company |
4th March, 2009 |
Affitech AS |
COPENHAGEN and OSLO, March 4 /PRNewswire/ -- Pharmexa A/S and Affitech AS
announced today that they have entered into a conditional agreement to merge
the two companies by means of a share for
|
| Bavarian Nordic Updates on Phase I/II Studies With Breast Cancer Vaccine |
23rd February, 2009 |
|
KVISTGARD, Denmark, February 23 /PRNewswire/ -- Bavarian Nordic today provided updated data from its clinical studies
with its breast cancer vaccine, MVA-BN(R)-HER2, in development as therapy of
|
| Affitech Acquires Pharmexa's Diabody Technology |
28th October, 2008 |
Affitech AS |
OSLO, Norway, October 28 /PRNewswire/ -- Affitech AS, the human
therapeutic antibody company, today announced that it had acquired the full
rights to the innovative diabody technology originally
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 468 times since April 2007, the link to the organisation's website has been followed 62 times Recent Search Terms used to find this page: pharmexa | Pharmexa | Pharmexa | Pharmexa | pharmexa san diego | pharmexa | pharmexa | Pharmexa | Pharmexa | pharmexa | . Search for more companies in Hørsholm Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Pharmexa |
